These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Master protocols in clinical trials: a universal Swiss Army knife? Sudhop T; Brun NC; Riedel C; Rosso A; Broich K; Senderovitz T Lancet Oncol; 2019 Jun; 20(6):e336-e342. PubMed ID: 31162107 [TBL] [Abstract][Full Text] [Related]
6. The behavioral dynamics of clinical trials. Leventhal H; Nerenz DR; Leventhal EA; Love RR; Bendena LM Prev Med; 1991 Jan; 20(1):132-46. PubMed ID: 2008422 [TBL] [Abstract][Full Text] [Related]
7. Pathology is a necessary and informative tool in oncology clinical trials. Nagtegaal ID; West NP; van Krieken JH; Quirke P J Pathol; 2014 Jan; 232(2):185-9. PubMed ID: 24037805 [TBL] [Abstract][Full Text] [Related]
8. Quality assurance in clinical trials. Ottevanger PB; Therasse P; van de Velde C; Bernier J; van Krieken H; Grol R; De Mulder P Crit Rev Oncol Hematol; 2003 Sep; 47(3):213-35. PubMed ID: 12962897 [TBL] [Abstract][Full Text] [Related]
9. Oncologists' knowledge, attitudes and practices related to cancer treatment clinical trials. Kaanoi M; Braun KL; Gotay CC; Abrigo L Hawaii Med J; 2002 May; 61(5):91-5. PubMed ID: 12073745 [TBL] [Abstract][Full Text] [Related]
10. Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design? Prasad V; Vandross A J Cancer Res Clin Oncol; 2014 Apr; 140(4):521-4. PubMed ID: 24474554 [No Abstract] [Full Text] [Related]
11. Implementing the final rule. Alpert S Acad Emerg Med; 1999 Dec; 6(12):1188-9. PubMed ID: 10609918 [No Abstract] [Full Text] [Related]
12. Ethical challenges in cancer care. Latimer E J Palliat Care; 1992; 8(1):65-70. PubMed ID: 1583572 [No Abstract] [Full Text] [Related]
13. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. Zon R; Meropol NJ; Catalano RB; Schilsky RL J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967 [TBL] [Abstract][Full Text] [Related]
14. Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program. Kaluzny AD; Lacey LM; Warnecke R; Hynes DM; Morrissey J; Ford L; Sondik E Health Serv Res; 1993 Jun; 28(2):159-82. PubMed ID: 8514498 [TBL] [Abstract][Full Text] [Related]
15. Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program. Kaluzny A; Brawley O; Garson-Angert D; Shaw J; Godley P; Warnecke R; Ford L J Natl Cancer Inst; 1993 Dec; 85(23):1945-50. PubMed ID: 8230286 [TBL] [Abstract][Full Text] [Related]
16. Medical oncologists' participation in cancer clinical trials. Spaight SJ; Nash S; Finison LJ; Patterson WB Prog Clin Biol Res; 1984; 156():49-61. PubMed ID: 6473452 [No Abstract] [Full Text] [Related]
17. Accrual to cancer clinical trials: directions from the research literature. Gotay CC Soc Sci Med; 1991; 33(5):569-77. PubMed ID: 1962228 [TBL] [Abstract][Full Text] [Related]
18. Registration of trials and protocols. Staessen JA; Bianchi G Lancet; 2003 Sep; 362(9389):1009-10. PubMed ID: 14522528 [No Abstract] [Full Text] [Related]
20. Ecological analysis of the first generation of community clinical oncology programs. Schopler JH Health Serv Res; 1993 Apr; 28(1):69-95. PubMed ID: 8463110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]